Amgen Inc.

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: AMGN Category:

Description

Amgen delivered a mixed set of results for the previous quarter, with revenues well below analyst expectations but managed earnings beat. The company achieved significant quarterly sales for seven key brands and witnessed substantial volume growth across general medicine, inflammation, and hematology/oncology portfolios. The company’s product sales rose by 5% year-over-year, supported by an impressive 11% increase in volume, demonstrating strength across various regions. Within the General Medicine business, encompassing Repatha, Prolia, EVENITY, and Aimovig, the overall revenue for these four products surged by 21% in the quarter, primarily fueled by a 20% growth in volume. In bone health, Prolia reported a 14% year-over-year sales increase in the third quarter, buoyed by a 7% volume growth and higher net selling prices. EVENITY achieved significant sales of $307 million, propelled by a substantial 48% volume growth. Despite Otezla experiencing a 10% decline in sales, Amgen’s team remains optimistic about its growth potential, increasing investments to educate physicians and patients about its unique indication for psoriasis. ENBREL sales decreased, while TEZSPIRE exhibited strong growth. In the hematology/oncology segment, BLINCYTO sales grew impressively. Amgen also introduced Amgen Partners of Choice, a novel network that aims to unite Amgen’s oncology research and development specialists with renowned clinical leaders at eight research centers worldwide.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!